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Summary 
Activin A and other TGFβ family members have been shown to exhibit a certain 
degree of promiscuity between their family of receptors. We previously developed an 
efficient differentiation protocol using Activin A to obtain medium spiny neurons 
(MSNs) from human pluripotent stem cells (hPSCs). However, the mechanism 
underlying Activin A-induced MSN fate specification remains largely unknown. Here 
we begin to tease apart the different components of TGFβ pathways involved in 
MSN differentiation and demonstrate that Activin A acts exclusively via ALK4/5 
receptors to induce MSN progenitor fate during differentiation. Moreover, we show 
that Alantolactone, an indirect activator of Smad2/3 signalling, offers an alternative 
approach to differentiate hPSC-derived forebrain progenitors into MSNs. Further fine 
tuning of TGFβ pathway by inhibiting BMP signalling with LDN193189 achieves 
accelerated MSN fate specification. This study therefore establishes an essential 
role for TGFβ signalling in human MSN differentiation and provides a fully defined 
and highly adaptable small molecule-based protocol to obtain MSNs from hPSCs.    
  
Introduction 
Medium spiny neurons (MSNs) are the principal projection neurons of the striatum 
which receive synaptic inputs from both glutamatergic and dopaminergic afferents as 
part of the basal ganglia circuit. This arrangement is crucial for cognitive and motor 
functions, which include action selection, motor control, sequence learning, habit 
formation and more. Degeneration/dysfunction of MSNs has already been 
established as an early pathology in Huntington’s disease, where MSNs are the 
principle, albeit not the only, neurons affected (1). There is also growing evidence for 
cortico- and midbrain-striatal systems’ imbalance as an etiological factor in a 
spectrum of neurodevelopmental and neuropsychiatric disorders such as autism and 
schizophrenia (2-5).     
In vitro-derived human medium spiny neurons (MSNs) from pluripotent stem cells 
(hPSCs) are an invaluable tool for the study of striatal development and function, as 
well as a potential therapy in regenerative medicine. Previous works towards 
differentiating hPSCs into MSNs have focused on ventralising anterior neural 
progenitors produced from stromal cell co-culture, embryoid body or monolayer 
neural induction (6-9). These groups acted on the principle that FOXG1+ cells in the 
developing telencephalon are exposed to opposing gradients of the ventralising 
morphogen SHH and its repressor GLI3, which is expressed in dorsal tissues 
together with BMP and Wnt proteins (10). Inducing SHH and inhibiting Wnt signalling 
in forebrain progenitors proved to be a successful strategy to generate pan-subpallial 
progenitors expressing FOXG1, OTX2, GSH2 and NKX2.1. However, CTIP2, 
FOXP1 and FOXP2 markers specific to lateral ganglionic eminence (LGE), the 
birthplace of MSNs, appeared quite late and only alongside DARPP32 expression 
after neuronal maturation (9). Preferential induction of these markers was not 
apparent which suggests that these marker expressions are merely indicators of 
MSNs being born rather than a driving force for MSN induction. It is therefore likely 
that the MSNs generated using SHH and antagonists of Wnt result from the 
induction of pan-subpallial markers rather than a direct instructive effect towards 
LGE progenitors. 
In contrast, we discovered that Activin A (Activin), a member of the TGFβ family of 
ligands, rapidly induces specific expression of MSN precursor markers in forebrain 
progenitors derived from hPSCs (11). The TGF-β family of proteins, including TGF-β, 
Activins and BMPs, are involved in many aspects of cell proliferation, lineage 
determination, differentiation, motility, adhesion, and death (12). Their intracellular 
effector proteins, the Smads, are phosphorylated upon receptor-ligand binding and 
translocate to the nucleus where they can activate gene transcription. Activins act 
through activin type II receptors A/B (ActR-IIA/B) and activin-like kinase receptors 
4/5 (ALK4/5) to recruit Smad2/3. Phosphorylated Smad2 (pSmad2) was previously 
detected to co-localise with transcription factor DLX2 throughout the ganglionic 
eminences (GE) (13, 14). The two proteins were also confirmed to interact in vivo by 
immunoprecipitation, and pSmad2 was found to bind to the DLX2 gene enhancer by 
chromatin immunoprecipitation. In line with these findings, we observed robust 
induction of not only subpallial DLX2 and GSH2 expression but also of LGE-specific 
CTIP2 expression (11). Moreover, we demonstrated in the same study that Activin 
acts independently of SHH and blockade of ALK4/5 receptors abolished any 
response to Activin, suggesting signalling mechanism via the ALK4/5-Smad2/3 
pathway. 
Use of small molecules for hPSC-differentiation offers many advantages over 
recombinant proteins – namely their increased stability and consistency in activity, as 
well as much lower usage cost. Alantolactone is a compound extracted from the 
roots of Inula helenium (Compositae), which grows in Europe and Asia, and was 
found to have anti-proliferative effects that have fuelled extensive research into a 
role in tumour suppression (15, 16). The mechanism by which Alantolactone 
suppresses tumours is shown to involve disruption of Cripto-1, an endogenous 
Activin antagonist, binding to the ActR-IIA (17).  
Here, we investigated how fine tuning the TGFβ signalling to simultaneously induce 
Activin and inhibit BMP signalling affects MSN differentiation. Our study provides 
evidence that Alantolactone can replace Activin in inducing MSN fate from hPSCs. 
Thus, we provide a fully defined and highly adaptable small molecule-based MSN 
differentiation protocol.  
Methods 
Cell Culture and MSN Differentiation 
MSNs were differentiated from the following hESC lines: H7 hESCs, H9 hESCs, and 
HUES9 iCas9 hESCs. MSNs were obtained and maintained as described previously 
(11). For inhibitor experiments, from 10DIV (days of in vitro differentiation) cells were 
treated with Activin alone (25ng/mL) or plus the following inhibitors: SB431542 
(10µM), SB525334 (1µM), LY2109761 (5µM) or LDN193189 (100nM). 
Concentrations for SB431542 and LDN193189 we chosen the same as in neural 
induction step of MSN differentiation protocol (11). Concentrations for SB525334 and 
LY2109761 we chosen based on published literature (18, 19). In Alantolactone 
experiments, cells were supplemented with Alantolactone from 10DIV until 40DIV at 
the following concentrations: 0nM, 62.5nM, 125nM, 250nM, 500nM. 
RT-PCR 
Total mRNA was extracted from TRIzol lysates using the PureLink RNA mini kit 
(Ambion). RT-PCR was completed using 2ug mRNA and the EvoScript kit (Roche). 
MesaGreen kit was used to perform qPCR using 200pg mRNA/reaction. The 
following primers were used: 
Gene Forward Primer Reverse Primer 
GAPDH ACGACCCCTTCATTGACCTCAACT ATATTTCTCGTGGTTCACACCCAT 
β-ACTIN TCACCACCACGGCCGAGCG TCTCCTTCTGCATCCTGTCG 
CTIP2 CTCCGAGCTCAGGAAAGTGTC TCATCTTTACCTGCAATGTTCTCC 
GSH2 TCACTAGCACGCAACTCCTG TTTTCACCTGCTTCTCCGAC 
DLX2 ACTACCCCTGGTACCACCAGAC TCTGCTCTCAGTCTCTGGCGAGTTCTC 
NKX2.1 CGCATCCAATCTCAAGGAAT TGTGCCCAGAGTGAAGTTTG 
PAX6 AATAACCTGCCTATGCAACCC AACTTGAACTGGAACTGACACAC 
 
Immunocytochemistry 
Cells were fixed for immunostaining in 3.7% PFA for 15 minutes. Cells were 
incubated with primary antibodies in blocking solution overnight at 4°C. Following 
three PBS-T washes, Alexa-Fluor secondary antibodies (Thermo Fisher Scientific) 
were added at 1:1000 for 1 hour at ambient temperature in the dark. Cells were 
stained with DAPI at 1:1000 (Thermo Fisher Scientific). The following primary 
antibodies were used for the immunofluorescence studies: rat anti-CTIP2 (Abcam 
#ab18465, 1:500), rabbit anti-FOXP2 (Abcam #ab16046, 1:500), mouse anti-FOXP1 
(Abcam #ab32010, 1:800), rabbit anti-GSH2 (Merck Millipore #ABN162, 1:500), 
mouse anti-ISL1 (Developmental Studies Hybridoma Bank #39.4D5, 1:500), rabbit 
anti-FOXG1 (Abcam # ab18259, 1:1000), rabbit anti-DARPP32 (Santa Cruz 
Biotechnology #sc-11365, 1:500). Cell fate markers were counted as a proportion of 
DAPI from at least 5 randomly selected fields/sample in ImageJ (imagej.net) blind to 
the experimental condition.  
Western Blot 
Equal amounts of proteins for each sample were separated on 4-12% Bolt Bis-Tris 
Plus gels (Thermo Fisher Scientific) and transferred via electro-blotting to a PVDF 
membrane (0.45 µm pore size, GE Healthcare). Membranes were incubated with 
primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated 
secondary antibodies (Abcam) for 1 hour. The following primary antibodies were 
used for the western blot studies: rabbit anti-pSmad2-Ser465/467 (Cell Signalling 
Technology #3101, 1:1000), rabbit anti-Smad2/3 (Cell Signalling Technology #3102, 
1:1000), mouse anti-GAPDH (Abcam #8245, 1:10000). All blot images were 
quantified in ImageJ blind to the experimental condition. 
Statistical Analysis 
All quantified data were plotted in Prism 6 (GraphPad Software) and are reported as 
mean ± SEM with sample sizes for each test indicated in the figure legends. Data 
was pooled from either multiple hESC lines or independent experiments within the 
same line or a combination of both to acquire at least three independent 
observations per group. Box-and-whisker plots depict data for each condition: centre 
line – median,’+’ – mean, box limits – upper and lower quartiles, whiskers – 2.5 and 
97.5 percentiles. Normal distribution of data was assessed with Kolmogorov-Smirnov 
test and homogeneity of variance was tested with Levene’s test. Statistical analysis 
was performed using two-tailed Student’s t-test, one-/two-way ANOVA tests followed 
by Bonferroni’s correction for multiple comparisons if applicable or non-parametric 
Mann-Whitney test for not normally distributed data. Results were considered 
statistically significant at P<0.05 and only significant results are reported on the 
graphs.  
Results 
Differential roles for TGFβ signalling in LGE fate induction in hPSCs 
Activin and other TGFβ family members have been shown to exhibit a certain degree 
of promiscuity between their family of receptors (20). In order to verify that Activin 
was acting via the ALK4/5 receptors to induce LGE gene upregulation, Activin 
treatment of forebrain progenitors at 10 days in vitro (DIV) was supplemented with 
an ALK4/5 inhibitor, SB431542 (Figure 1A). At 19DIV, Activin-induced expression of 
CTIP2 and GSH2 was abolished in the presence of the inhibitor confirming receptor-
specific activity (Figure 1B). Moreover, there was no change in DLX2 and NKX2.1 
level in the Activin condition, further highlighting direct LGE fate specification by 
Activin versus alternative GE progenitor fates.   
With the aim of teasing apart the different TGFβ pathways downstream of Activin 
induction in hPSC-derived forebrain progenitors, we performed a screen of three 
chemical inhibitors selective for different ALK receptors. SB525334 (SB5) is a dual 
ALK4/5 inhibitor and LY2109761 (LY) is a selective ALK5 inhibitor while both are 
inactive at ALK2/3/6. LDN193189 (LDN) is a selective ALK2/3/6 inhibitor that only 
affects BMP signalling. Cells were treated with Activin with or without inhibitors from 
10DIV and then lysed for RNA extraction 1 or 6 days later (Figure 1A, 1C). Levels of 
mRNA from all conditions and time points were normalised to the control condition at 
10DIV+1. 
At 10DIV+1, Activin alone induced an increase in expression of CTIP2, GSH2 and 
NKX2.1 compared to the untreated control condition (Figure 1C). This effect was 
mostly abolished by all the inhibitors, with LDN consistently showing the least 
inhibition across all genes. At 10DIV+6, the level of CTIP2 rose by 6-fold in the 
Activin condition, which was completely inhibited by SB5 and LY, the TGFβ/Activin 
pathway inhibitors. Interestingly, the addition of LDN to Activin caused an 18-fold 
increase in CTIP2 mRNA levels, although this was also completely abolished by the 
further addition of both SB5 and LY. GSH2 expression increased 11-fold in the 
control condition, whereas Activin alone only led to a 7.6-fold increase. Again, Activin 
plus LDN saw a modest 13.2-fold increase in GSH2 compared to the control. 
NKX2.1 mRNA level dropped to nearly undetectable levels in all conditions. PAX6 
expression was consistently lower than the subpallial markers and remained 
constant in all conditions across all time points. 
The novel discovery from the Activin plus LDN condition was verified using a second 
qPCR experiment repeating the control, Activin and Activin+LDN conditions at the 
same timepoints (Figure 1D). The addition of LDN induced a significant increase in 
CTIP2 mRNA compared to all conditions at 10DIV+1 and the control condition at 
10DIV+6. Again, there was a large and significant upregulation of GSH2 in the 
control condition (39.6-fold), which was closely matched by the Activin treatment. 
Activin+LDN supplementation caused a further increase (56.7-fold), which was 
significantly different from both control and Activin alone. 
Inhibition of BMP signalling accelerates MSN differentiation 
The novel finding that BMP signalling blockade by LDN could enhance Activin-
induced LGE gene upregulation prompted further enquiry into its effects on protein 
expression at the MSN stage of differentiation. Similar to the previous experiment, 
differentiating neural progenitors were treated with Activin with or without LDN from 
10DIV onwards. Activin supplementation in both conditions continued throughout the 
experiment, while addition of LDN was stopped at 20DIV based on a preliminary 
experiment (Figure 2A). At 20DIV, both Activin and Activin+LDN treatments 
produced comparatively high yields of neuronal precursors expressing LGE markers 
CTIP2, FOXP1, FOXP2, ISL1, GSH2 and forebrain marker FOXG1 (Figure 2B, 2C). 
Only FOXP2+ cell numbers were significantly higher in Activin condition compared to 
Activin+LDN.  
The percentage of CTIP2+ neurons increased between 20DIV and 40DIV in all 
conditions, from around 30% to 70% (Figure 2D, 2E). Similarly, DARPP32+ neuron 
population increased in both conditions from less than 10% at 25DIV to up to 40% at 
40DIV. Interestingly, there were significantly higher percentages of CTIP2+ neurons 
at 30DIV and 35DIV in Activin+LDN condition compared to Activin alone (Figure 2E). 
This effect was also present in the number of DARPP32+ neurons, which was more 
than doubled at 30DIV in Activin+LDN condition in contrast to Activin alone. 
However, by 40DIV the numbers of CTIP2+ and DARPP32+ neurons in the Activin 
condition reached a similar level to that of Activin+LDN condition. These results 
suggest that inhibition of BMP signalling accelerate differentiation of LGE-like 
progenitors into MSNs. 
Efficient induction of MSN fate by TGFβ small molecule agonist 
Next, we investigated if Alantolactone, a small molecule agonist of TGFβ signalling, 
presents a suitable alternative to Activin to generate MSNs from hPSCs. 
Differentiating forebrain progenitors were treated with either Activin or Alantolactone 
(250nM) from 10DIV onwards (Figure 3A). At 20DIV, we observed a similar degree 
of LGE fate specification in both conditions as evidenced by comparatively high 
yields of cells expressing several well-established LGE and nascent MSN markers 
(Figure 3B). There were no significant differences between Activin and 
Alantolactone treatments across all markers analysed (Figure 3C).      
To determine the most optimal Alantolactone concentration for generating MSNs, we 
quantified CTIP2+ neurons at 40DIV in five different conditions ranging from 0nM to 
500nM Alantolactone and compared results to the basal control and Activin cultures 
(Figure 3D, 3E). The percentage of CTIP2+ neurons significantly increased in 
response to Alantolactone in a dose-dependent manner within a 0-250nM range 
compared to control (Figure 3E). However, the number of CTIP2+ neurons at 500nM 
was similar to negative control levels, suggesting that too high activation of TGFβ 
pathway might be detrimental for MSN differentiation or survival. At 250nM, 
Alantolactone treatment yielded a similar number of CTIP2+ neurons compared to 
Activin (Figure 3E). Further experiment using the optimal concentration 
Alantolactone (250nM) produced high percentages of DARPP32+, FOXP1+, and 
FOXP2+ neurons that were indistinguishable from our ‘gold-standard’ obtained by 
Activin (Figure 3F, 3G). We have tested LDN supplementation as in previous 
experiments, but it did not potentiate the effects of Alantolactone on MSN 
differentiation (data not shown). 
To validate that Alantolactone can activate TGF-β pathway in neuronal precursors 
we have analysed pSmad2/3 levels in LGE-like progenitors at 10DIV+5. We 
observed a similar significant increase in pSMAD2/3 levels in both Activin and 
Alantolactone conditions compared to the basal control cultures (Figure 3H). Taken 
together, these results indicate that Alantolactone indeed offers an alternative 
solution to Activin to efficiently generate MSNs from hPSC-derived forebrain 
progenitors via Smad2/3 pathway. 
Discussion 
In this study we have begun to dissect the different components that could be 
contributing to the mechanism by which activation of TGFβ signalling induces LGE 
characteristics in hPSC-derived forebrain progenitors. Previous work using a 
zebrafish model of development demonstrated that the presence of Nodal, a TGF-β 
family member that shares some receptors with Activin, is necessary for Shh 
expression across the CNS and likely acts upstream of Shh to establish dorso-
ventral patterning of the telencephalon (21). Another group more recently showed 
that Smad3, an intracellular effector of TGF-β, Nodal and Activin signalling, is highly 
expressed in the subpallium throughout development, further highlighting the 
importance of these signalling pathways (22).  
We have demonstrated that Activin exerts its effects via both ALK5 and ALK4, as 
dual ALK4/5 inhibitor was consistently more effective at inhibiting LGE marker up-
regulation than ALK5 inhibitor alone. Furthermore, ALK4/5 inhibition in earlier 
experiments showed a complete abolishment of LGE marker expression, both at the 
mRNA and protein levels (11). This is in agreement with the fact that Activin binds to 
both receptors in vivo and that they have the same intracellular effector proteins 
Smad2/3, which should have the same transcriptional targets (23). 
Through the screening of multiple TGFβ family inhibitors, it was found that blocking 
BMP signalling at progenitor stage (10-20DIV) could enhance Activin-mediated 
induction of LGE marker gene expressions, leading to a change in the kinetics of the 
differentiation. Our findings suggest that blockade of BMP signalling accelerates 
MSN differentiation but does not increase the overall production of MSNs. BMPs are 
heavily involved in dorsal neural tube development but are specifically expressed in 
the dorsal midline of the forebrain (24). It is therefore possible that the enhancement 
of Activin-induced LGE gene expression by BMP receptor inhibition is down to the 
suppression of a dorso-medial telencephalic fate, encouraging a more ventro-lateral 
patterning of the cells towards an LGE fate. As Activins and BMPs share some 
common ActR-II, it is also possible that LDN, which inhibits BMP Type I receptors 
ALK1/2/3/6, causes more Type II receptors to be available for Activin to bind and 
increase Smad2/3 phosphorylation (23). 
We demonstrate for the first time that Alantolactone, a TGFβ small molecule agonist, 
offers a suitable alternative to Activin to efficiently generate MSNs from hPSC-
derived forebrain progenitors. Previous research suggests that Alantolactone 
indirectly activates Smad2/3 signalling downstream of Activin by making ActR-II 
more bioavailable (17). A recent study in zebrafish, demonstrated that Alantolactone 
activated TGFβ signalling in a concentration-dependent manner to subsequently 
cause disruption of the circadian clock (25). This is in line with our observations of 
similar Activin- and Alantolactone-induced increases in pSmad2 levels and a dose-
dependent effect of Alantolactone on efficiency of MSN differentiation. This novel 
finding provides further evidence that MSN fate is specified in forebrain progenitors 
via Smad2/3 pathway activation.  
In conclusion, we offer a fully defined and highly adaptable small molecule-based 
protocol via Smad2/3 pathway to induce LGE fate in differentiating forebrain 
progenitors and to subsequently obtain high yield of MSNs. We provide extensive 
evidence to show that both Activin and Alantolactone, activators of TGFβ-Smad2/3 
signalling, efficiently generate MSNs from hPSCs. We also describe an option to 
further fine tune TGFβ activation in LGE progenitors by transiently inhibiting BMP 
signalling. This step accelerates MSN differentiation, which may prove to be useful 
for some hPSC lines that are slower in responding to differentiation cues or have 
intrinsically higher levels of BMP activity. Our study therefore establishes an 
essential role for TGFβ signalling in human MSN differentiation from PSCs. 
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Figure Legends 
 
Figure 1 - Differential roles for TGFβ signalling in LGE fate induction in hPSCs   
(A) Schematic timeline of MSN differentiation.  
(B) qPCR data from RNA extracted at 19DIV after treatment with Activin (25ng/ml) 
alone or plus SB431542 (10µM) as shown in (A). Data show mean RQ ± SEM 
relative to control (n = 6, 6 and 2, respectively). 
(C) qPCR data from RNA extracted 1 or 6 days after treatment that began at 10DIV. 
Cells were untreated (control) or treated with Activin (25ng/ml), or Activin plus 
SB525334 (1µM), LY2109761 (5µM) or LDN193189 (100nM). Data show mean RQ 
± SEM relative to the 10DIV+1 control (n = 2 per group). 
(D) A repeat of the experiment in (C) with just control, Activin and Activin plus LDN 
conditions to confirm the LDN effects on CTIP2 and GSH2 upregulation. Data show 
mean RQ ± SEM relative to the 10DIV+1 control (n = 3 per group; *P<0.05, 
**P<0.01, ***P<0.001; two-way ANOVA with post-hoc Bonferroni). 
 
Figure 2 - Inhibition of BMP signalling accelerates Activin effects 
(A) Schematic timeline of MSN differentiation.  
(B and C) Neuronal precursors expressing LGE and forebrain markers in Activin and 
Activin+LDN cultures at 20DIV labelled and quantified for FOXP1, FOXP2, ISL1, 
GSH2, and FOXG1 (n = 20 per group; **P<0.01; two-tailed Student’s t-test). Box-
and-whisker plots depict data for each condition. Scale bars 50 µm. 
(D and E) MSNs in Activin and Activin+LDN cultures at 30DIV and 40DIV labelled 
and quantified for CTIP2 and DARPP32 (n = 10 per group; *P<0.05, **P<0.01; two-
way ANOVA with post-hoc Bonferroni). Data are presented as mean ± SEM. Scale 
bar 50 µm. 
 
Figure 3 - Efficient induction of MSN by TGFβ small molecule agonist 
(A) Schematic timeline of MSN differentiation.  
(B and C) Neuronal precursors expressing LGE and forebrain markers in Activin and 
Alantolactone (250nM) cultures at 20DIV labelled and quantified for CTIP2, FOXP1, 
FOXP2, ISL1, GSH2, and FOXG1 (n = 20 per group). Box-and-whisker plots depict 
data for each condition. Scale bars 50 µm. 
(D and E) MSNs in Activin and varying concentrations of Alantolactone conditions at 
40DIV labelled and quantified for CTIP2 (n = 40 per group; ***P<0.001 vs Control 
condition; n.s. = non-significant; one-way ANOVA with post-hoc Bonferroni). Box-
and-whisker plots depict data for each condition. Scale bar 50 µm. 
(F and G) MSNs in Activin and Alantolactone (250nM) cultures at 40DIV labelled and 
quantified for DARPP32, FOXP1 and FOXP2 (DARPP32: n = 10 per group; 
FOXP1/2: n = 30 per group). Box-and-whisker plots depict data for each condition. 
Scale bars 50 µm. 
(H) Phosphorylation of Smad2/3 is greatly increased in Activin- and Alantolactone-
treated cultures compared to basal control condition at 10DIV+5 (n = 3 per group; 
*P<0.05 vs Control condition; one-way ANOVA with post-hoc Bonferroni). Bar plots 
depict mean ± SEM for each condition with individual data points shown with 
markers. 
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Summary 
Activin A and other TGFβ family members have been shown to exhibit a certain 
degree of promiscuity between their family of receptors. We previously developed an 
efficient differentiation protocol using Activin A to obtain medium spiny neurons 
(MSNs) from human pluripotent stem cells (hPSCs). However, the mechanism 
underlying Activin A-induced MSN fate specification remains largely unknown. Here 
we begin to tease apart the different components of TGFβ pathways involved in 
MSN differentiation and demonstrate that Activin A acts exclusively via ALK4/5 
receptors to induce MSN progenitor fate during differentiation. Moreover, we show 
that Alantolactone, an indirect activator of Smad2/3 signalling, offers an alternative 
approach to differentiate hPSC-derived forebrain progenitors into MSNs. Further fine 
tuning of TGFβ pathway by inhibiting BMP signalling with LDN193189 achieves 
accelerated MSN fate specification. This study therefore establishes an essential 
role for TGFβ signalling in human MSN differentiation and provides a fully defined 
and highly adaptable small molecule-based protocol to obtain MSNs from hPSCs.    
  
Introduction 
Medium spiny neurons (MSNs) are the principal projection neurons of the striatum 
which receive synaptic inputs from both glutamatergic and dopaminergic afferents as 
part of the basal ganglia circuit. This arrangement is crucial for cognitive and motor 
functions, which include action selection, motor control, sequence learning, habit 
formation and more. Degeneration/dysfunction of MSNs has already been 
established as an early pathology in Huntington’s disease, where MSNs are the 
principle, albeit not the only, neurons affected (1). There is also growing evidence for 
cortico- and midbrain-striatal systems’ imbalance as an etiological factor in a 
spectrum of neurodevelopmental and neuropsychiatric disorders such as autism and 
schizophrenia (2-5).     
In vitro-derived human medium spiny neurons (MSNs) from pluripotent stem cells 
(hPSCs) are an invaluable tool for the study of striatal development and function, as 
well as a potential therapy in regenerative medicine. Previous works towards 
differentiating hPSCs into MSNs have focused on ventralising anterior neural 
progenitors produced from stromal cell co-culture, embryoid body or monolayer 
neural induction (6-9). These groups acted on the principle that FOXG1+ cells in the 
developing telencephalon are exposed to opposing gradients of the ventralising 
morphogen SHH and its repressor GLI3, which is expressed in dorsal tissues 
together with BMP and Wnt proteins (10). Inducing SHH and inhibiting Wnt signalling 
in forebrain progenitors proved to be a successful strategy to generate pan-subpallial 
progenitors expressing FOXG1, OTX2, GSH2 and NKX2.1. However, CTIP2, 
FOXP1 and FOXP2 markers specific to lateral ganglionic eminence (LGE), the 
birthplace of MSNs, appeared quite late and only alongside DARPP32 expression 
after neuronal maturation (9). Preferential induction of these markers was not 
apparent which suggests that these marker expressions are merely indicators of 
MSNs being born rather than a driving force for MSN induction. It is therefore likely 
that the MSNs generated using SHH and antagonists of Wnt result from the 
induction of pan-subpallial markers rather than a direct instructive effect towards 
LGE progenitors. 
In contrast, we discovered that Activin A (Activin), a member of the TGFβ family of 
ligands, rapidly induces specific expression of MSN precursor markers in forebrain 
progenitors derived from hPSCs (11). The TGF-β family of proteins, including TGF-β, 
Activins and BMPs, are involved in many aspects of cell proliferation, lineage 
determination, differentiation, motility, adhesion, and death (12). Their intracellular 
effector proteins, the Smads, are phosphorylated upon receptor-ligand binding and 
translocate to the nucleus where they can activate gene transcription. Activins act 
through activin type II receptors A/B (ActR-IIA/B) and activin-like kinase receptors 
4/5 (ALK4/5) to recruit Smad2/3. Phosphorylated Smad2 (pSmad2) was previously 
detected to co-localise with transcription factor DLX2 throughout the ganglionic 
eminences (GE) (13, 14). The two proteins were also confirmed to interact in vivo by 
immunoprecipitation, and pSmad2 was found to bind to the DLX2 gene enhancer by 
chromatin immunoprecipitation. In line with these findings, we observed robust 
induction of not only subpallial DLX2 and GSH2 expression but also of LGE-specific 
CTIP2 expression (11). Moreover, we demonstrated in the same study that Activin 
acts independently of SHH and blockade of ALK4/5 receptors abolished any 
response to Activin, suggesting signalling mechanism via the ALK4/5-Smad2/3 
pathway. 
Use of small molecules for hPSC-differentiation offers many advantages over 
recombinant proteins – namely their increased stability and consistency in activity, as 
well as much lower usage cost. Alantolactone is a compound extracted from the 
roots of Inula helenium (Compositae), which grows in Europe and Asia, and was 
found to have anti-proliferative effects that have fuelled extensive research into a 
role in tumour suppression (15, 16). The mechanism by which Alantolactone 
suppresses tumours is shown to involve disruption of Cripto-1, an endogenous 
Activin antagonist, binding to the ActR-IIA (17).  
Here, we investigated how fine tuning the TGFβ signalling to simultaneously induce 
Activin and inhibit BMP signalling affects MSN differentiation. Our study provides 
evidence that Alantolactone can replace Activin in inducing MSN fate from hPSCs. 
Thus, we provide a fully defined and highly adaptable small molecule-based MSN 
differentiation protocol.  
Methods 
Cell Culture and MSN Differentiation 
MSNs were differentiated from the following hESC lines: H7 hESCs, H9 hESCs, and 
HUES9 iCas9 hESCs. MSNs were obtained and maintained as described previously 
(11). For inhibitor experiments, from 10DIV (days of in vitro differentiation) cells were 
treated with Activin alone (25ng/mL) or plus the following inhibitors: SB431542 
(10µM), SB525334 (1µM), LY2109761 (5µM) or LDN193189 (100nM). 
Concentrations for SB431542 and LDN193189 we chosen the same as in neural 
induction step of MSN differentiation protocol (11). Concentrations for SB525334 and 
LY2109761 we chosen based on published literature (18, 19). In Alantolactone 
experiments, cells were supplemented with Alantolactone from 10DIV until 40DIV at 
the following concentrations: 0nM, 62.5nM, 125nM, 250nM, 500nM. 
RT-PCR 
Total mRNA was extracted from TRIzol lysates using the PureLink RNA mini kit 
(Ambion). RT-PCR was completed using 2ug mRNA and the EvoScript kit (Roche). 
MesaGreen kit was used to perform qPCR using 200pg mRNA/reaction. The 
following primers were used: 
Gene Forward Primer Reverse Primer 
GAPDH ACGACCCCTTCATTGACCTCAACT ATATTTCTCGTGGTTCACACCCAT 
β-ACTIN TCACCACCACGGCCGAGCG TCTCCTTCTGCATCCTGTCG 
CTIP2 CTCCGAGCTCAGGAAAGTGTC TCATCTTTACCTGCAATGTTCTCC 
GSH2 TCACTAGCACGCAACTCCTG TTTTCACCTGCTTCTCCGAC 
DLX2 ACTACCCCTGGTACCACCAGAC TCTGCTCTCAGTCTCTGGCGAGTTCTC 
NKX2.1 CGCATCCAATCTCAAGGAAT TGTGCCCAGAGTGAAGTTTG 
PAX6 AATAACCTGCCTATGCAACCC AACTTGAACTGGAACTGACACAC 
 
Immunocytochemistry 
Cells were fixed for immunostaining in 3.7% PFA for 15 minutes. Cells were 
incubated with primary antibodies in blocking solution overnight at 4°C. Following 
three PBS-T washes, Alexa-Fluor secondary antibodies (Thermo Fisher Scientific) 
were added at 1:1000 for 1 hour at ambient temperature in the dark. Cells were 
stained with DAPI at 1:1000 (Thermo Fisher Scientific). The following primary 
antibodies were used for the immunofluorescence studies: rat anti-CTIP2 (Abcam 
#ab18465, 1:500), rabbit anti-FOXP2 (Abcam #ab16046, 1:500), mouse anti-FOXP1 
(Abcam #ab32010, 1:800), rabbit anti-GSH2 (Merck Millipore #ABN162, 1:500), 
mouse anti-ISL1 (Developmental Studies Hybridoma Bank #39.4D5, 1:500), rabbit 
anti-FOXG1 (Abcam # ab18259, 1:1000), rabbit anti-DARPP32 (Santa Cruz 
Biotechnology #sc-11365, 1:500). Cell fate markers were counted as a proportion of 
DAPI from at least 5 randomly selected fields/sample in ImageJ (imagej.net) blind to 
the experimental condition.  
Western Blot 
Equal amounts of proteins for each sample were separated on 4-12% Bolt Bis-Tris 
Plus gels (Thermo Fisher Scientific) and transferred via electro-blotting to a PVDF 
membrane (0.45 µm pore size, GE Healthcare). Membranes were incubated with 
primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated 
secondary antibodies (Abcam) for 1 hour. The following primary antibodies were 
used for the western blot studies: rabbit anti-pSmad2-Ser465/467 (Cell Signalling 
Technology #3101, 1:1000), rabbit anti-Smad2/3 (Cell Signalling Technology #3102, 
1:1000), mouse anti-GAPDH (Abcam #8245, 1:10000). All blot images were 
quantified in ImageJ blind to the experimental condition. 
Statistical Analysis 
All quantified data were plotted in Prism 6 (GraphPad Software) and are reported as 
mean ± SEM with sample sizes for each test indicated in the figure legends. Data 
was pooled from either multiple hESC lines or independent experiments within the 
same line or a combination of both to acquire at least three independent 
observations per group. Box-and-whisker plots depict data for each condition: centre 
line – median,’+’ – mean, box limits – upper and lower quartiles, whiskers – 2.5 and 
97.5 percentiles. Normal distribution of data was assessed with Kolmogorov-Smirnov 
test and homogeneity of variance was tested with Levene’s test. Statistical analysis 
was performed using two-tailed Student’s t-test, one-/two-way ANOVA tests followed 
by Bonferroni’s correction for multiple comparisons if applicable or non-parametric 
Mann-Whitney test for not normally distributed data. Results were considered 
statistically significant at P<0.05 and only significant results are reported on the 
graphs.  
Results 
Differential roles for TGFβ signalling in LGE fate induction in hPSCs 
Activin and other TGFβ family members have been shown to exhibit a certain degree 
of promiscuity between their family of receptors (20). In order to verify that Activin 
was acting via the ALK4/5 receptors to induce LGE gene upregulation, Activin 
treatment of forebrain progenitors at 10 days in vitro (DIV) was supplemented with 
an ALK4/5 inhibitor, SB431542 (Figure 1A). At 19DIV, Activin-induced expression of 
CTIP2 and GSH2 was abolished in the presence of the inhibitor confirming receptor-
specific activity (Figure 1B). Moreover, there was no change in DLX2 and NKX2.1 
level in the Activin condition, further highlighting direct LGE fate specification by 
Activin versus alternative GE progenitor fates.   
With the aim of teasing apart the different TGFβ pathways downstream of Activin 
induction in hPSC-derived forebrain progenitors, we performed a screen of three 
chemical inhibitors selective for different ALK receptors. SB525334 (SB5) is a dual 
ALK4/5 inhibitor and LY2109761 (LY) is a selective ALK5 inhibitor while both are 
inactive at ALK2/3/6. LDN193189 (LDN) is a selective ALK2/3/6 inhibitor that only 
affects BMP signalling. Cells were treated with Activin with or without inhibitors from 
10DIV and then lysed for RNA extraction 1 or 6 days later (Figure 1A, 1C). Levels of 
mRNA from all conditions and time points were normalised to the control condition at 
10DIV+1. 
At 10DIV+1, Activin alone induced an increase in expression of CTIP2, GSH2 and 
NKX2.1 compared to the untreated control condition (Figure 1C). This effect was 
mostly abolished by all the inhibitors, with LDN consistently showing the least 
inhibition across all genes. At 10DIV+6, the level of CTIP2 rose by 6-fold in the 
Activin condition, which was completely inhibited by SB5 and LY, the TGFβ/Activin 
pathway inhibitors. Interestingly, the addition of LDN to Activin caused an 18-fold 
increase in CTIP2 mRNA levels, although this was also completely abolished by the 
further addition of both SB5 and LY. GSH2 expression increased 11-fold in the 
control condition, whereas Activin alone only led to a 7.6-fold increase. Again, Activin 
plus LDN saw a modest 13.2-fold increase in GSH2 compared to the control. 
NKX2.1 mRNA level dropped to nearly undetectable levels in all conditions. PAX6 
expression was consistently lower than the subpallial markers and remained 
constant in all conditions across all time points. 
The novel discovery from the Activin plus LDN condition was verified using a second 
qPCR experiment repeating the control, Activin and Activin+LDN conditions at the 
same timepoints (Figure 1D). The addition of LDN induced a significant increase in 
CTIP2 mRNA compared to all conditions at 10DIV+1 and the control condition at 
10DIV+6. Again, there was a large and significant upregulation of GSH2 in the 
control condition (39.6-fold), which was closely matched by the Activin treatment. 
Activin+LDN supplementation caused a further increase (56.7-fold), which was 
significantly different from both control and Activin alone. 
Inhibition of BMP signalling accelerates MSN differentiation 
The novel finding that BMP signalling blockade by LDN could enhance Activin-
induced LGE gene upregulation prompted further enquiry into its effects on protein 
expression at the MSN stage of differentiation. Similar to the previous experiment, 
differentiating neural progenitors were treated with Activin with or without LDN from 
10DIV onwards. Activin supplementation in both conditions continued throughout the 
experiment, while addition of LDN was stopped at 20DIV based on a preliminary 
experiment (Figure 2A). At 20DIV, both Activin and Activin+LDN treatments 
produced comparatively high yields of neuronal precursors expressing LGE markers 
CTIP2, FOXP1, FOXP2, ISL1, GSH2 and forebrain marker FOXG1 (Figure 2B, 2C). 
Only FOXP2+ cell numbers were significantly higher in Activin condition compared to 
Activin+LDN.  
The percentage of CTIP2+ neurons increased between 20DIV and 40DIV in all 
conditions, from around 30% to 70% (Figure 2D, 2E). Similarly, DARPP32+ neuron 
population increased in both conditions from less than 10% at 25DIV to up to 40% at 
40DIV. Interestingly, there were significantly higher percentages of CTIP2+ neurons 
at 30DIV and 35DIV in Activin+LDN condition compared to Activin alone (Figure 2E). 
This effect was also present in the number of DARPP32+ neurons, which was more 
than doubled at 30DIV in Activin+LDN condition in contrast to Activin alone. 
However, by 40DIV the numbers of CTIP2+ and DARPP32+ neurons in the Activin 
condition reached a similar level to that of Activin+LDN condition. These results 
suggest that inhibition of BMP signalling accelerate differentiation of LGE-like 
progenitors into MSNs. 
Efficient induction of MSN fate by TGFβ small molecule agonist 
Next, we investigated if Alantolactone, a small molecule agonist of TGFβ signalling, 
presents a suitable alternative to Activin to generate MSNs from hPSCs. 
Differentiating forebrain progenitors were treated with either Activin or Alantolactone 
(250nM) from 10DIV onwards (Figure 3A). At 20DIV, we observed a similar degree 
of LGE fate specification in both conditions as evidenced by comparatively high 
yields of cells expressing several well-established LGE and nascent MSN markers 
(Figure 3B). There were no significant differences between Activin and 
Alantolactone treatments across all markers analysed (Figure 3C).      
To determine the most optimal Alantolactone concentration for generating MSNs, we 
quantified CTIP2+ neurons at 40DIV in five different conditions ranging from 0nM to 
500nM Alantolactone and compared results to the basal control and Activin cultures 
(Figure 3D, 3E). The percentage of CTIP2+ neurons significantly increased in 
response to Alantolactone in a dose-dependent manner within a 0-250nM range 
compared to control (Figure 3E). However, the number of CTIP2+ neurons at 500nM 
was similar to negative control levels, suggesting that too high activation of TGFβ 
pathway might be detrimental for MSN differentiation or survival. At 250nM, 
Alantolactone treatment yielded a similar number of CTIP2+ neurons compared to 
Activin (Figure 3E). Further experiment using the optimal concentration 
Alantolactone (250nM) produced high percentages of DARPP32+, FOXP1+, and 
FOXP2+ neurons that were indistinguishable from our ‘gold-standard’ obtained by 
Activin (Figure 3F, 3G). We have tested LDN supplementation as in previous 
experiments, but it did not potentiate the effects of Alantolactone on MSN 
differentiation (data not shown). 
To validate that Alantolactone can activate TGF-β pathway in neuronal precursors 
we have analysed pSmad2/3 levels in LGE-like progenitors at 10DIV+5. We 
observed a similar significant increase in pSMAD2/3 levels in both Activin and 
Alantolactone conditions compared to the basal control cultures (Figure 3H). Taken 
together, these results indicate that Alantolactone indeed offers an alternative 
solution to Activin to efficiently generate MSNs from hPSC-derived forebrain 
progenitors via Smad2/3 pathway. 
Discussion 
In this study we have begun to dissect the different components that could be 
contributing to the mechanism by which activation of TGFβ signalling induces LGE 
characteristics in hPSC-derived forebrain progenitors. Previous work using a 
zebrafish model of development demonstrated that the presence of Nodal, a TGF-β 
family member that shares some receptors with Activin, is necessary for Shh 
expression across the CNS and likely acts upstream of Shh to establish dorso-
ventral patterning of the telencephalon (21). Another group more recently showed 
that Smad3, an intracellular effector of TGF-β, Nodal and Activin signalling, is highly 
expressed in the subpallium throughout development, further highlighting the 
importance of these signalling pathways (22).  
We have demonstrated that Activin exerts its effects via both ALK5 and ALK4, as 
dual ALK4/5 inhibitor was consistently more effective at inhibiting LGE marker up-
regulation than ALK5 inhibitor alone. Furthermore, ALK4/5 inhibition in earlier 
experiments showed a complete abolishment of LGE marker expression, both at the 
mRNA and protein levels (11). This is in agreement with the fact that Activin binds to 
both receptors in vivo and that they have the same intracellular effector proteins 
Smad2/3, which should have the same transcriptional targets (23). 
Through the screening of multiple TGFβ family inhibitors, it was found that blocking 
BMP signalling at progenitor stage (10-20DIV) could enhance Activin-mediated 
induction of LGE marker gene expressions, leading to a change in the kinetics of the 
differentiation. Our findings suggest that blockade of BMP signalling accelerates 
MSN differentiation but does not increase the overall production of MSNs. BMPs are 
heavily involved in dorsal neural tube development but are specifically expressed in 
the dorsal midline of the forebrain (24). It is therefore possible that the enhancement 
of Activin-induced LGE gene expression by BMP receptor inhibition is down to the 
suppression of a dorso-medial telencephalic fate, encouraging a more ventro-lateral 
patterning of the cells towards an LGE fate. As Activins and BMPs share some 
common ActR-II, it is also possible that LDN, which inhibits BMP Type I receptors 
ALK1/2/3/6, causes more Type II receptors to be available for Activin to bind and 
increase Smad2/3 phosphorylation (23). 
We demonstrate for the first time that Alantolactone, a TGFβ small molecule agonist, 
offers a suitable alternative to Activin to efficiently generate MSNs from hPSC-
derived forebrain progenitors. Previous research suggests that Alantolactone 
indirectly activates Smad2/3 signalling downstream of Activin by making ActR-II 
more bioavailable (17). A recent study in zebrafish, demonstrated that Alantolactone 
activated TGFβ signalling in a concentration-dependent manner to subsequently 
cause disruption of the circadian clock (25). This is in line with our observations of 
similar Activin- and Alantolactone-induced increases in pSmad2 levels and a dose-
dependent effect of Alantolactone on efficiency of MSN differentiation. This novel 
finding provides further evidence that MSN fate is specified in forebrain progenitors 
via Smad2/3 pathway activation.  
In conclusion, we offer a fully defined and highly adaptable small molecule-based 
protocol via Smad2/3 pathway to induce LGE fate in differentiating forebrain 
progenitors and to subsequently obtain high yield of MSNs. We provide extensive 
evidence to show that both Activin and Alantolactone, activators of TGFβ-Smad2/3 
signalling, efficiently generate MSNs from hPSCs. We also describe an option to 
further fine tune TGFβ activation in LGE progenitors by transiently inhibiting BMP 
signalling. This step accelerates MSN differentiation, which may prove to be useful 
for some hPSC lines that are slower in responding to differentiation cues or have 
intrinsically higher levels of BMP activity. Our study therefore establishes an 
essential role for TGFβ signalling in human MSN differentiation from PSCs. 
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Figure Legends 
Figure 1 - Differential roles for TGFβ signalling in LGE fate induction in hPSCs   
(A) Schematic timeline of MSN differentiation.  
(B) qPCR data from RNA extracted at 19DIV after treatment with Activin (25ng/ml) 
alone or plus SB431542 (10µM) as shown in (A). Data show mean RQ ± SEM 
relative to control (n = 6, 6 and 2, respectively). 
(C) qPCR data from RNA extracted 1 or 6 days after treatment that began at 10DIV. 
Cells were untreated (control) or treated with Activin (25ng/ml), or Activin plus 
SB525334 (1µM), LY2109761 (5µM) or LDN193189 (100nM). Data show mean RQ 
± SEM relative to the 10DIV+1 control (n = 2 per group). 
(D) A repeat of the experiment in (C) with just control, Activin and Activin plus LDN 
conditions to confirm the LDN effects on CTIP2 and GSH2 upregulation. Data show 
mean RQ ± SEM relative to the 10DIV+1 control (n = 3 per group; *P<0.05, 
**P<0.01, ***P<0.001; two-way ANOVA with post-hoc Bonferroni). 
Figure 2 - Inhibition of BMP signalling accelerates Activin effects 
(A) Schematic timeline of MSN differentiation.  
(B and C) Neuronal precursors expressing LGE and forebrain markers in Activin and 
Activin+LDN cultures at 20DIV labelled and quantified for FOXP1, FOXP2, ISL1, 
GSH2, and FOXG1 (n = 20 per group; **P<0.01; two-tailed Student’s t-test). Box-
and-whisker plots depict data for each condition. Scale bars 50 µm. 
(D and E) MSNs in Activin and Activin+LDN cultures at 30DIV and 40DIV labelled 
and quantified for CTIP2 and DARPP32 (n = 10 per group; *P<0.05, **P<0.01; two-
way ANOVA with post-hoc Bonferroni). Data are presented as mean ± SEM. Scale 
bar 50 µm. 
Figure 3 - Efficient induction of MSN by TGFβ small molecule agonist 
(A) Schematic timeline of MSN differentiation.  
(B and C) Neuronal precursors expressing LGE and forebrain markers in Activin and 
Alantolactone (250nM) cultures at 20DIV labelled and quantified for CTIP2, FOXP1, 
FOXP2, ISL1, GSH2, and FOXG1 (n = 20 per group). Box-and-whisker plots depict 
data for each condition. Scale bars 50 µm. 
(D and E) MSNs in Activin and varying concentrations of Alantolactone conditions at 
40DIV labelled and quantified for CTIP2 (n = 40 per group; ***P<0.001 vs Control 
condition; n.s. = non-significant; one-way ANOVA with post-hoc Bonferroni). Box-
and-whisker plots depict data for each condition. Scale bar 50 µm. 
(F and G) MSNs in Activin and Alantolactone (250nM) cultures at 40DIV labelled and 
quantified for DARPP32, FOXP1 and FOXP2 (DARPP32: n = 10 per group; 
FOXP1/2: n = 30 per group). Box-and-whisker plots depict data for each condition. 
Scale bars 50 µm. 
(H) Phosphorylation of Smad2/3 is greatly increased in Activin- and Alantolactone-
treated cultures compared to basal control condition at 10DIV+5 (n = 3 per group; 
*P<0.05 vs Control condition; one-way ANOVA with post-hoc Bonferroni). Bar plots 
depict mean ± SEM for each condition with individual data points shown with 
markers. 
